$SLN News
Last published 3w ago
- 3w agoBRZEOPCHSLNRXOAre BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
- 3w agoAGIOIRONKROSPTGX+1A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare
- 3w agoSLNSilence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, GermanyBusiness WireAll-Cash Transaction Values Silence Therapeutics at Approximately $1.3 Billion Price of $20.00 Per ADS in Cash Represents 130% Premium to Silence’s Closing ADS Price on October 16, 2026 Transaction Delivers
- 3w agoSLNMerck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA AssetBusiness WirePurchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeutics is a UK-headquartered biotechnology company with a
- 2mo agoSLNSilence Therapeutics to Participate in Three September Investor ConferencesBusiness WireSilence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following
- 2mo agoSLNSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsBusiness WireSilence Therapeutics plc, (NASDAQ:SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced
- 3mo agoSLNSilence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public OfferingBusiness WireSilence Therapeutics plc ("Silence" or the "Company") , a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has
- 3mo agoSLNSilence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary SharesBusiness WireSilence Therapeutics plc ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has
- 3mo agoSCKTABCLSLNNTHIThe Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major MilestonesGlobeNewswireDENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT)
- 3mo agoSLNSilence Therapeutics Webcast to Discuss Topline Results from Phase 2 SANRECO Study of Divesiran - SILENCE THERAPEUTICS PLCEarnings Call TranscriptsThanks everyone for joining us. With me today are Ian Ross, our Chairman and Interim Principal Executive Officer, who will provide some opening comments, and Steve Romano, our Chief R&D Officer, who will review the San R
- 3mo agoSLNSilence Therapeutics Webcast to Discuss Topline Results from Phase 2 SANRECO Study of Divesiran - SILENCE THERAPEUTICS PLCEarnings Call TranscriptsThanks everyone for joining us. With me today are Ian Ross, our Chairman and Interim Principal Executive Officer, who will provide some opening comments, and Steve Romano, our Chief R&D Officer, who will review the San R
- 3mo agoSLNSilence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class ProfileBusiness WireTrial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed
- 3mo agoSLNSilence Therapeutics Reports Second Quarter 2026 Financial and Business ResultsBusiness WireSilence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30,
- 3mo agoSLNSilence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia VeraBusiness WireSilence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase
- 5mo agoSLNSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraBusiness WireNew analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final dose Phase 2
- 5mo agoSLNSilence Therapeutics to Participate in Jefferies Global Healthcare ConferenceBusiness WireSilence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside
- 6mo agoSLNSilence Therapeutics to Participate in H.C. Wainwright BioConnect Investor ConferenceBusiness WireSilence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics,
- 6mo agoSLNSilence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial ResultsBusiness WirePhase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global
- 8mo agoSLNSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireTopline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026 Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company
- 11mo agoSLNSilence Therapeutics Announces Leadership ChangesBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the
- 12mo agoSLNSilence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceBusiness WireSilence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies
- 1y agoSLNSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness WireSANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or
- 1y agoSLNSilence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)Business WireRapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26 Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage
- 1y agoSLNSilence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoSLNSilence Therapeutics to Participate in September Investor ConferencesBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the
- 1y agoSLNSilence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire‒ Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV ‒ SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025 Silence
- 1y agoSLNSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraBusiness WireUpdated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track
- 1y agoSLNSilence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsBusiness WireCompany further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today
- 1y agoSLNSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsBusiness WireMr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence"
- 1y agoSLNSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company
- 1y agoSLNSilence Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateBusiness WireThe Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global
- 1y agoSLNSilence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025Business WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial
- 1y agoSLNSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingBusiness WireNew divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients Silence also announces first subject dosed in Phase 2 study of divesiran in PV
- 1y agoSLNSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines,
- 1y agoSLNSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingBusiness WireNew zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time-averaged Lp(a) results to further evaluate potential
- 1y agoSLNSilence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines,
- 1y agoSLNSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines,
- 2y agoSLNSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera PatientsBusiness WireDivesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at
- 2y agoSLNSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)Business WireStudy demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"),
- 2y agoSLNSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceBusiness WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsBusiness WireSilence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
- 2y agoSLNSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)Business WirePublished findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and
- 2y agoSLNSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsBusiness WireSilence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to host conference call and webcast today at 8 a.m. EDT / 12 p.m.
- 2y agoSLNSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)Business WireStudy met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 Silence
- 2y agoSLNSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024Business WireSilence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered